INTRODUCTION {#s1}
============

In contrast to the steady increase in survival for most cancers, advances have been slow for non-small cell lung cancer (NSCLC), for which the 5-year survival rate is currently 18%. The low rate is partly contributed to that more than one-half of cases are diagnosed at a distant stage, for which 5-year relative survival is 4% \[[@R1]\]. Platinum agents combined with another kind of cytotoxic drugs have been the mainstay of treatment for advanced NSCLC regardless of various therapy responses between patients \[[@R2]\]. Therefore, novel molecular biomarkers are required to be identified for further development of individualized therapy.

*P53* signaling pathway has been demonstrated to be crucial in regulating chemotherapeutic effects of cancer treatment by initiating cellular responses such as DNA repair, cell cycle arrest, apoptosis, and senescence \[[@R3], [@R4]\]. Murine double minute 4 (*MDM4*), structurally homologous protein of murine double minute 2 (*MDM2*), contributes to cancer susceptibility and progression through its capacity to regulate transcriptional activity of the tumor suppressor *p53* \[[@R5]\]. The interaction between *MDM4* and *p53* in the regulation of cancer was investigated in several previous studies \[[@R6], [@R7]\]. As a key protein involved in the process of DNA damage response, inhibition of *p53* by *MDM2* and *MDM4* can result in delayed DNA repair \[[@R8]--[@R10]\]. However, later studies revealed a novel role of *MDM4* in *p53*-mediated intrinsic apoptotic pathway and the non-overlapping role in regulating *p53* activity with *MDM2* \[[@R11], [@R12]\]. Considering the previous conflicting reports about the function of *MDM4* in inhibiting *p53* activity, the relationship between *MDM4* and cancers needs to be further investigated.

In the last decades, an increasing number of researches had been focused on posttranscriptional regulation of gene expression by microRNAs (miRNAs) and their potential effects on the development and prognosis of cancer. miRNAs are small, single-stranded, non-coding RNAs that regulate gene expression through canonical base pairing with complementary seed sequence located in the 3′-untranslated region (UTR) of target mRNAs \[[@R13]\]. Association between genetic variations in this region of *MDM4* gene and cancers had been investigated in previous studies. The A-allele of *MDM4* rs4245739A\>C (SNP34091) was associated with increased expression of *MDM4* mRNA and protein levels by miR-191-5p regulation in ovarian carcinomas and sensitivity for chemotherapy \[[@R14]\]. Another study reported the regulation of *MDM4* rs4245739 polymorphism by two miRNAs (miR-191-5p and miR-887-3p), and the A-allele of rs4245739 may be associated with an increased risk for prostate cancer \[[@R15]\].

However, in spite of the well-known role in tumor pathogenesis and progression, few genetic variants of *MDM4* had been found to be associated with NSCLC. To fill this gap, we chose to focus on potential miRNAs-binding *MDM4* polymorphisms in order to detecting variants that alter treatment efficacy of platinum-based chemotherapy. In the present study, four SNPs located at the 3′-UTRs of *MDM4* gene were selected for further investigation.

RESULTS {#s2}
=======

Patient characteristics and genotype frequencies {#s2_1}
------------------------------------------------

Demographic and clinical characteristics of patients in two study sets were presented in Table [1](#T1){ref-type="table"}. In the Discovery set, 456 (71.0%) were male and 382 (59.5%) were smokers. All patients were diagnosed with advanced inoperable NSCLC and had received platinum-based chemotherapy, with 40.8% of stage III and 59.2% of stage IV. Variables of the Replication set showed no statistically differences when compared with the Discovery set. Genotype frequencies of four *MDM4* polymorphisms were in Hardy--Weinberg equilibrium (*P* \> 0.05). The investigated SNPs were classified by models including genotypic, dominant, recessive, or additive. There was no significant difference in genotype distributions of all selected SNPs according to clinical factors ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

###### Basic characteristics of patients from the two cohorts

  Variables           Discovery set (N, %)(n=642)   Replication set (N, %)(n=330)   *χ*^2^   *P*^a^
  ------------------- ----------------------------- ------------------------------- -------- --------
  Age (years)                                                                                
   \< 58              333 (51.9)                    171 (51.8)                      0.001    0.988
   ≥ 58               309 (48.1)                    159 (48.2)                               
  Gender                                                                                     
   Male               456 (71.0)                    234 (70.9)                      0.001    0.969
   Female             186 (29.0)                    96 (29.1)                                
  Smoking history                                                                            
   Non-smokers        260 (40.5)                    144 (43.6)                      0.884    0.347
   Smokers            382 (59.5)                    186 (56.4)                               
  ECOG PS                                                                                    
   0-1                593 (92.4)                    297 (90.0)                      1.582    0.209
   2                  49 (7.6)                      33 (10.0)                                
  Chemotherapy                                                                               
   NP/NC              236 (36.8)                    115 (34.8)                      1.126    0.771
   GP/GC              174 (27.1)                    95 (28.8)                                
   TP/TC              192 (29.9)                    95 (28.8)                                
   DP/DC              40 (6.2)                      25 (7.6)                                 
  TNM stage                                                                                  
   III                262 (40.8)                    119 (36.1)                      2.063    0.151
   IV                 380 (59.2)                    211 (63.9)                               
  Histological type                                                                          
   Adeno              398 (62.0)                    213 (64.5)                      2.057    0.358
   SQC                147 (22.9)                    66 (20.0)                                
   Others             97 (15.1)                     51 (15.5)                                

Adeno adenocarcinoma, SQC squamous cell carcinoma, ^a^ *p*-values derived from *χ*^2^ test.

Survival analysis {#s2_2}
-----------------

### Discovery set {#s2_2_1}

The median overall survival (OS) and progression-free survival (PFS) (53 patients were excluded for PFS analysis because of incomplete information) for all the patients was 19.27 (95% CI, 17.64-20.90) and 10.07 (95% CI, 8.61-11.53) months, respectively. Patients with TNM stage IV and infrequently histological subtypes had significant worse OS (aHR=1.28, 95% CI, 1.06-1.54, *P* = 0.012; and aHR=1.35, 95% CI, 1.03-1.76, *P* = 0.027; respectively) compared to patients with TNM stage III and adenocarcinoma. In addition, ECOG PS was related to PFS and patients with higher scores showed a higher risk of recurrence or metastasis (aHR=1.70, 95% CI, 1.16-2.49, *P* = 0.006), whereas other clinical factors were not independent predictive factors ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

Using *MDM4* genotypes as categorical variables, two SNPs (rs10900598 and rs4245739) were significantly associated with OS (*P* = 0.017 and *P* = 0.015), but not with PFS (*P* = 0.429 and *P* = 0.302; [Supplementary Table S3](#SD1){ref-type="supplementary-material"}). For rs10900598, HRs were significantly lower for individuals with CC genotype compared with AA genotype (aHR=0.65, 95% CI, 0.46-0.93, *P* = 0.017), whereas AC genotype showed no significance after adjusting for clinical factors. In the dominant and recessive model, the association between C variant allele and better survival was concluded (for CC+AC genotype HR, 0.79; 95% CI, 0.64-0.97; *P* = 0.026; for CC genotype HR, 0.67; 95% CI, 0.47-0.95; *P* = 0.025). In contrast, carriers of rs4245739 AC genotype were associated with prolonged survival (aHR=0.71, 95% CI, 0.52-0.98, *P* = 0.037), whereas patients with CC genotype didn\'t remain significant after clinical factors were adjusted. Although not reaching statistical significance, rs4245739 CC genotype showed a similar trend of association with OS. In addition, in the dominant model, C allele carriers had better survival compared with A allele carriers (for C allele HR, 0.67; 95% CI, 0.50-0.90; *P* = 0.007) (Table [2](#T2){ref-type="table"}). Furthermore, we included age, TNM stage, histological type, rs10900598 dominant model, and rs4245739 dominant model in the multivariate Cox\'s regression analysis. The results suggested that TNM stage (*P*= 0.008), histological type (*P*= 0.014), rs10900598 dominant model (*P*= 0.023), and rs4245739 dominant model (*P*= 0.007) were independent predictive factors for OS (Table [3](#T3){ref-type="table"}). The Kaplan-Meier curves of OS according to *MDM4* SNPs were shown in Figure [1](#F1){ref-type="fig"} (Figure [1A](#F1){ref-type="fig"} for rs10900598; Figure [1B](#F1){ref-type="fig"} for rs4245739).

###### Association between *MDM4* SNPs and OS of patients in each set and in pooled populations

  SNPs             Discovery set   Replication set       Pooled                                                                                                                                                            
  ---------------- --------------- --------------------- -------- ------------------ ------- ----- --------------------- ------- ------------------ ------- ----- --------------------- --------------- ------------------ ---------------
  **rs10900598**                                                                                                                                                                                                           
  AA               476             17.80 (15.44-20.16)   0.017    Ref.                       233   16.40 (13.64-19.16)   0.007   Ref.                       709   17.57 (15.93-19.21)   2.15\* 10^-4^   Ref.               
  AC               115             20.00 (17.45-22.55)            0.86 (0.68-1.10)   0.227   73    24.03 (17.85-30.22)           0.77 (0.57-1.06)   0.107   188   21.27 (18.11-24.42)                   0.83 (0.69-1.00)   0.055
  CC               49              25.77 (15.92-35.61)            0.65 (0.46-0.93)   0.017   24    29.77 (23.57-35.96)           0.49 (0.29-0.82)   0.007   73    27.43 (22.35-32.51)                   0.60 (0.45-0.80)   0.001
  dominant                                                                                                                                                                                                                 
  CC+AC            164             21.90 (18.73-25.07)   0.008    0.79 (0.64-0.97)   0.026   97    25.60 (21.17-30.03)   0.004   0.68 (0.51-0.91)   0.008   261   22.63 (20.07-25.19)   1.59\* 10^-4^   0.75 (0.64-0.89)   0.001
  AA               476             17.80 (15.44-20.16)            Ref.                       233   16.40 (13.64-19.16)           Ref.                       709   17.57 (15.93-19.21)                   Ref.               
  recessive                                                                                                                                                                                                                
  CC               49              25.77 (15.92-35.61)   0.023    0.67 (0.47-0.95)   0.025   24    29.77 (23.57-35.96)   0.012   0.52 (0.31-0.88)   0.013   73    27.43 (22.35-32.51)   0.001           0.62 (0.47-0.83)   0.001
  AA+AC            591             18.67 (16.97-20.36)            Ref.                       306   17.90 (15.67-20.13)           Ref.                       897   18.30 (16.91-19.69)                   Ref.               
  additive                         NA                    NA       0.82 (0.71-0.96)   0.011         NA                    NA      0.73 (0.59-0.90)   0.003         NA                    NA              0.79 (0.70-0.90)   1.67\* 10^-4^
  **rs4245739**                                                                                                                                                                                                            
  AA               568             18.67 (16.83-20.50)   0.015    Ref.                       294   17.70 (15.50-19.91)   0.018   Ref.                       862   18.00 (16.60-19.40)   0.001           Ref.               
  AC               61              21.27 (15.07-27.47)            0.71 (0.52-0.98)   0.037   30    27.90 (19.76-36.04)           0.71 (0.46-1.10)   0.121   91    24.47 (18.68-30.26)                   0.71 (0.55-0.91)   0.008
  CC               13              31.27 (26.49-36.05)            0.50 (0.25-1.02)   0.055   6     30.63 (16.29-44.97)           0.49 (0.18-1.35)   0.166   19    31.27 (27.17-35.36)                   0.50 (0.28-0.89)   0.019
  dominant                                                                                                                                                                                                                 
  CC+AC            74              25.37 (15.95-34.78)   0.005    0.67 (0.50-0.90)   0.007   36    29.80 (23.58-36.02)   0.006   0.67 (0.44-1.01)   0.051   110   26.40 (20.56-32.24)   2.06\* 10^-4^   0.67 (0.53-0.85)   0.001
  AA               568             18.67 (16.83-20.50)            Ref.                       294   17.70 (15.50-19.91)           Ref.                       862   18.00 (16.60-19.40)                   Ref.               
  recessive                                                                                                                                                                                                                
  CC               13              31.27 (26.49-36.05)   0.066    0.52 (0.26-1.05)   0.069   6     30.63 (16.29-44.97)   0.085   0.52 (0.19-1.41)   0.198   19    31.27 (27.17-35.36)   0.017           0.52 (0.29-0.93)   0.026
  AA+AC            629             19.10 (17.46-20.74)            Ref.                       324   19.03 (16.44-21.70)           Ref.                       953   19.07 (17.67-20.46)                   Ref.               
  additive                         NA                    NA       0.71 (0.56-0.90)   0.005         NA                    NA      0.71 (0.50-0.99)   0.043         NA                    NA              0.71 (0.59-0.86)   4.99\* 10^-4^

OS overall survival, m months, Ref. reference, NA not available, HR hazard ratio, CI confidence interval, *P*~L-R~ Log-Rank *P*;

^a^ survival derived from Kaplan--Meier analysis;

^b^ HRs, 95% CIs and their corresponding *p*-values were calculated using multivariate Cox proportional hazard models, adjusted for all clinical factors.

###### Multivariate Cox\'s regression analysis of prognostic factors for overall survival in Discovery set

  Variables                HR (95% CI)        *P*
  ------------------------ ------------------ -------
  Age (≥ 58 vs. \< 58)     1.21 (1.01-1.45)   0.053
  TNM stage (IV vs. III)   1.29 (1.07-1.55)   0.008
  Histological type                           0.014
  Adeno                    Ref.               
  SQC                      1.26 (1.00-1.58)   0.049
  Others                   1.40 (1.08-1.82)   0.011
  rs10900598                                  
  dominant                 0.78 (0.64-0.97)   0.023
  rs4245739                                   
  dominant                 0.67 (0.50-0.90)   0.007

Adeno adenocarcinoma, SQC squamous cell carcinoma. All the variables yielding *P*-values\< 0.1 in the univariate analysis were used for multivariate Cox\'s regression.

![Kaplan-Meier curves of\
**A**. OS and rs10900598 in Discovery set, **B**. OS and rs4245739 in Discovery set, **C**. number of variant alleles from two SNPs in Discovery set, and **D**. number of variant alleles from two SNPs in Pooled populations.](oncotarget-08-16313-g001){#F1}

To better define the influence of *MDM4* SNPs on OS, we performed a subgroup analysis stratified by clinical factors. The results suggested that the above associations were more pronounced in lung adenocarcinoma (LAC) subjects. Patients with rs10900598 CC genotype and rs4245739 AC genotype had marginally prolonged OS than those with wild-type AA genotype (31.20 vs. 19.10, *P* = 0.039; and 32.70 vs. 19.90, *P* = 0.042; respectively). Subgroup multivariate Cox\'s regression analysis revealed that relevant aHRs were 0.64 and 0.67, respectively (*P* = 0.048 and *P* = 0.047). In addition, the above significant models of rs10900598 and rs4245739 also showed similar relationship with OS in LAC patients (for dominant, additive model of rs10900598 aHR=0.73, 95% CI, 0.55-0.95, *P* = 0.020, and aHR=0.79, 95% CI, 0.65-0.96, *P* = 0.017, respectively; for dominant, additive model of rs4245739 aHR=0.65, 95% CI, 0.45-0.93, *P* = 0.020, and aHR=0.69, 95% CI, 0.50-0.94, *P* = 0.019, respectively) ([Supplementary Table S4](#SD1){ref-type="supplementary-material"}).

Replication set and pooled analysis {#s2_3}
-----------------------------------

The median OS and PFS (4 patients were excluded for PFS analysis because of incomplete information) for the Replication set was 19.07 (95% CI, 16.44-21.70) and 7.33 (95% CI, 5.95-8.71) months, respectively. In this second group, we concluded that rs10900598 CC genotype was associated with better OS (aHR=0.49, 95% CI, 0.29-0.82, *P* = 0.007). The dominant model (*P* = 0.008), recessive model (*P* = 0.013), and additive model (*P* = 0.003) of rs10900598 also showed statistically significant association. For rs4245739, the Kaplan-Meier plots of OS were significant in genotypic and dominant model (*P* = 0.018 and *P* = 0.006). However, we failed to detect the differences of OS in patients with rs4245739 polymorphisms except for the additive model after adjusting for all other covariates (aHR=0.71, 95% CI, 0.50-0.99, *P* = 0.043) (Table [2](#T2){ref-type="table"}).

The pooled analysis of two sets confirmed the previously observed association with OS for rs10900598 (for CC+AC genotype HR, 0.75, 95% CI, 0.64-0.89, *P* = 0.001; for CC genotype HR, 0.62; 95% CI, 0.47-0.83; *P* = 0.001; for additive model HR, 0.79, 95% CI, 0.70-0.90; *P* = 1.67\*10^-4^), as well as for rs4245739 (for CC+AC genotype HR, 0.67, 95% CI, 0.53-0.85, *P* = 0.001; for CC genotype HR, 0.52; 95% CI, 0.29-0.93; *P* = 0.026; for additive model HR, 0.71, 95% CI, 0.59-0.86; *P* = 4.99\*10^-4^) (Table [2](#T2){ref-type="table"}).

Combined effects of the rs10900598 and rs4245739 on survival {#s2_4}
------------------------------------------------------------

We performed an exploratory analysis to investigate the combined effects of *MDM4* rs10900598 and rs4245739 polymorphisms, which had a significant association with OS in the individual SNP analysis, on survival outcomes. When we grouped patients according to the number of variant alleles (i.e., 0, 1, 2, 3, or 4), OS was increased with increasing number of variant alleles in a stepwise manner. In the Discovery set, OS for patients with four variant alleles was 33.93 (95% CI, 20.86-47.00) as compared with 31.27 (95% CI, 16.75-45.78), 26.30 (95% CI, 16.69-35.91), 19.77 (95% CI, 16.97-22.56), and 17.20 (95% CI, 14.85-19.55) months for those with three, two, one, and zero variant alleles, respectively (*P* = 0.004, Figure [1C](#F1){ref-type="fig"}). Multivariate Cox\'s proportional hazard analysis showed that, compared with the reference group of patients with zero variant allele, those with one, two, three and four variant alleles had aHRs of 0.80, 0.67, 0.44, and 0.36 respectively (*P* ~trend~ =0.010; Table [5](#T5){ref-type="table"}). In the pooled analysis, the Kaplan-Meier plots and log-rank tests confirmed the combined effects of the two SNPs on survival (*P* = 2.0\*10^-6^, Figure [1D](#F1){ref-type="fig"}). In addition, compared with patients with zero variant allele, those with one, two, three and four variant alleles had aHRs of 0.76, 0.62, 0.42, and 0.35 respectively (*P* ~trend~ = 3.3\*10^-5^) (Table [4](#T4){ref-type="table"}).

###### Correlations of significant *MDM4* SNPs with chemotherapy efficacy in Discovery set

  Variables        ORR (CR + PR)   DCR (CR + PR + SD)                                                                                      
  ---------------- --------------- -------------------- ------- ------------------ ------- ------------ ------- ------- ------------------ -------
  **rs10900598**                                                                                                                           
  AA               79 (16.6)       7.844                0.020   Ref.                       379 (79.6)   2.799   0.247   Ref.               
  AC               23 (20.0)                                    0.80 (0.47-1.36)   0.412   99 (86.1)                    0.65 (0.36-1.15)   0.139
  CC               16 (32.7)                                    0.35 (0.18-0.69)   0.003   38 (77.6)                    1.15 (0.56-2.35)   0.712
  dominant                                                                                                                                 
  CC+AC            39 (23.8)       4.186                0.041   0.62 (0.39-0.96)   0.034   137 (83.5)   1.197   0.274   0.78 (0.49-1.26)   0.317
  AA               79 (16.6)                                    Ref.                       379 (79.6)                   Ref.               
  recessive                                                                                                                                
  CC               16 (32.7)       7.131                0.008   0.37 (0.19-0.72)   0.003   38 (77.6)    0.321   0.571   1.24 (0.61-2.53)   0.561
  AA+AC            102 (17.3)                                   Ref.                       478 (80.9)                   Ref.               
  additive                         NA                   NA      0.64 (0.47-0.88)   0.005                NA      NA      0.93 (0.66-1.29)   0.646
  **rs4245739**                                                                                                                            
  AA               99 (17.4)       4.140                0.126   Ref.                       457 (80.5)   0.471   0.790   Ref.               
  AC               16 (26.2)                                    0.53 (0.28-1.01)   0.050   51 (83.6)                    0.79 (0.38-1.62)   0.516
  CC               4 (30.8)                                     0.54 (0.15-1.88)   0.331   10 (76.9)                    1.34 (0.35-5.12)   0.672
  dominant                                                                                                                                 
  CC+AC            20 (27.0)       3.994                0.046   0.53 (0.30-0.95)   0.033   61 (82.4)    0.164   0.686   0.87 (0.46-1.66)   0.674
  AA               99 (17.4)                                    Ref.                       457 (80.5)                   Ref.               
  recessive                                                                                                                                
  CC               4 (30.8)        1.315                0.251   0.58 (0.17-2.02)   0.388   10 (76.9)    0.121   0.728   1.37 (0.36-5.23)   0.647
  AA+AC            115 (18.3)                           Ref.                               508 (80.8)                   Ref.               
  additive                         NA                   NA      0.63 (0.40-0.99)   0.046                NA      NA      0.95 (0.57-1.60)   0.857

ORR objective response rate, DCR disease control rate, CR complete response, PR partial response, SD stable disease, Ref. reference, NA not available, OR, odds ratio; CI, confidence interval;

^a^ *p*-value derived from *χ*^2^ test;

^b^ ORs, 95% CIs and their corresponding *p*-values were calculated using multivariate logistic regression analysis, adjusted for all clinical factors.

###### Combined effects of *MDM4* rs10900598 and rs4245739 in Discovery set and in pooled populations

  No. ofVariant Alleles   Discovery set   Pooled                                                                                                                                   
  ----------------------- --------------- --------------------- ------- --------------------- ------- ------------ --------------------- ------------- --------------------------- ---------------
  0                       427 (66.5)      17.20 (14.85-19.55)   0.004   Ref.                          636 (65.4)   16.27 (14.45-18.08)   2.0\*10^-6^   Ref.                        
  1                       147 (22.9)      19.77 (16.97-22.56)           0.80 (0.64-1.00)      0.045   231 (23.8)   21.47 (18.69-24.24)                 0.76 (0.63-0.90)            0.002
  2                       55 (8.6)        26.30 (16.69-35.91)           0.67 (0.48-0.93)      0.016   87 (9.0)     27.90 (23.42-32.38)                 0.62 (0.48-0.80)            3.27\* 10^-4^
  3                       9 (1.4)         31.27 (16.75-45.78)           0.44 (0.19-1.00)      0.029   14 (1.4)     33.47 (21.18-45.76)                 0.42 (0.22-0.81)            0.016
  4                       4 (0.6)         33.93 (20.86-47.00)           0.36 (0.09-1.47)      0.015   4 (0.4)      33.93 (20.86-47.00)                 0.35 (0.09-1.40)            0.010
                                                                        *P* ~trend~ = 0.010                                                            *P* ~trend~ = 3.3\*10^-5^   

OS overall survival, m months, Ref. reference, HR hazard ratio, CI confidence interval, *P*~L-R~ Log-Rank *P*;

^a^ survival derived from Kaplan--Meier analysis;

^b^ HRs, 95% CIs and their corresponding *p*-values were calculated using multivariate Cox proportional hazard models, adjusted for all clinical factors.

*MDM4* polymorphisms and chemotherapy efficacy {#s2_5}
----------------------------------------------

Significant association with objective response rate (ORR) other than disease control rate (DCR) was manifested in 642 NSCLC patients of Discovery set (Table [5](#T5){ref-type="table"}). Association with ORR for rs10900598 (for CC+AC genotype HR, 0.62, 95% CI, 0.39-0.96, *P* = 0.034; for CC genotype HR, 0.37; 95% CI, 0.19-0.72; *P* = 0.003; for additive model HR, 0.64, 95% CI, 0.47-0.88; *P* = 0.005), as well as for rs4245739 (for CC+AC genotype HR, 0.53, 95% CI, 0.30-0.95, *P* = 0.033; for additive model HR, 0.63, 95% CI, 0.40-0.99; *P* = 0.046). However, the relationship with ORR was not proved significant in terms of rs4245739 CC genotype (*P* = 0.388).

Haplotype analysis {#s2_6}
------------------

Pairwise linkage disequilibriums for the four SNPs are presented, respectively, in [Supplementary Table S5](#SD1){ref-type="supplementary-material"}. Since the LD among these four SNPs of *MDM4* was incomplete in all subjects of the Discovery set, we hypothesized that variant haplotypes may have an influence on survival. Hence, we inferred twelve *MDM4* haplotypes, three of which had a frequency more than 0.10 and were selected for further analysis. The association between *MDM4* haplotypes with OS in the Discovery set was summarized in [Supplementary Table S6](#SD1){ref-type="supplementary-material"}. However, no significant difference in OS between patients with one or two copies and zero copies of *MDM4* haplotypes (G-A-A-A, G-A-C-A, and A-A-C-C) was concluded.

*In vitro* assay {#s2_7}
----------------

We used Mirnsnpscore software (<http://www.bigr.medisin.ntnu.no/mirsnpscore/>), based on *in silico* predictions of SNP effects on miRNA-based gene regulation, to assess the regulatory effect of the two significant SNPs. Mirnsnpscore could sorts selected SNPs and calculates a DeltaS score that reflects the potential effect on miRNA regulation. In particular, rs4245739 had the highest DeltaS score among the selected SNPs in the 3′-UTR of *MDM4* gene (DeltaS = 0.60 for miR-887-3p), while rs10900598 only had a DeltaS score of 0.17 for miR-3173. Hence, we examined whether there is an allele-specific effect of rs4245739 polymorphism on *MDM4* expression in NSCLC cells by the regulation of miR-887-3p by *in vitro* assay. The results indicated that miR-887-3p can significant lower luciferase activities in A549 cells co-transfected with rs4245739 C-allelic reporter constructs compared to negative control in all the experiments performed. Combining results from all the experiments, the average luciferase expression was reduced to 54.1% when considering the control groups as reference (*P* = 0.006, Figure [2](#F2){ref-type="fig"}).

![Dual luciferase reporter gene assays with constructs containing different alleles of *MDM4* 3′-UTR region or pGL3-control vector (empty) were co-transfected with miR-887-3p mimics or NC-miR in the NSCLC A549 cells\
The data are normalized to the luciferase activity observed with the empty vector, which is set to 1. All experiments were performed in triplicates and each value represents mean ± SD. \* *P* \< 0.05 compared with the empty control construct by *t*-tests. NC-miR, negative control miRNAs; NSCLC, non-small cell lung cancer.](oncotarget-08-16313-g002){#F2}

DISCUSSION {#s3}
==========

The principal finding of this trial is that two SNPs (rs10900598 and rs4245739), located at 3′-UTR of *MDM4* gene, contribute to clinical outcome of advanced NSCLC patients treated with platinum-based chemotherapy. In addition, the inhibition of rs4245739 CC genotype on gene expression by miR-887-3p regulation is demonstrated through *in vitro* assay. Given the role of *MDM4* as a key inhibitor of *p53* \[[@R16]\], it is biologically plausible that the *MDM4* SNPs may correlate with chemotherapy efficacy of DNA-damaging anti-cancer drugs.

The crucial role of *p53* as "molecular police" of genome integrity detection had been confirmed and clarified long ago. Modern pharmacology researches showed that anticancer drugs such as platinum could induce DNA damage of cancer cells and result in the activation of cell cycle checkpoints of G1-S and G2-M phases, which is followed by cell cycle arrest \[[@R17]\]. Then, the process of DNA repair, including mismatch repair (MMR) and nucleotide excision repair (NER) is started. Abrogation of cell cycle arrest will force cells into mitotic catastrophe or apoptosis and cell death \[[@R18]\]. Since the dysregulation of DNA repair is involved in chemotherapy resistance to NSCLC, it has been speculated that mutations of potentially targeted oncogenes or tumor suppressor genes should also be taken into consideration \[[@R19]\]. Therefore, variations in the DNA repair capacity including *p53* dysregulation by *MDM4* abnormal expression may play a role on clinical outcomes of advanced NSCLC patients.

miRNAs have been shown to modulate diverse biological processes, including DNA repair, by interacting with 3′-UTRs of potential targeted genes \[[@R20]\]. In addition, Several previous studies including genome-wide association study (GAWS) had confirmed the relationship between *MDM4* 3′-UTR SNPs and susceptibility of breast cancer, esophageal squamous cell carcinoma, and small cell lung cancer in different ethnic populations \[[@R21]--[@R23]\]. These results elucidated underlying mechanism that variations of *MDM4* 3′-UTR SNPs could alter the binding with specific miRNAs and modulate gene expression, ultimately affect cancer development. Beyond that, however, 3′-UTR of gene also harbors several regulatory motifs that determine mRNA turnover, stability, and localization together with different RNA-interacting factors \[[@R24]\]. To our knowledge, our study is the relatively largest investigation of *MDM4* gene SNPs in NSCLC prognosis.

In this present study, we demonstrated that *MDM4* rs10900598 and rs4245739 SNPs (located at 3′-UTR) were associated with increased overall survival in advanced NSCLC patients, and the results were even more apparent in LAC patients. This finding may be explained that patients with squamous cell carcinoma, adenosquamous carcinoma, or other histological types of lung cancer sometimes have complex somatic mutations driving treatment resistance when compared with adenocarcinoma, which may make that modest effect of genotypes on *MDM4* expression is overwhelmed. In the opinion of my team, any significant association for rs4245739 CC genotype may be weak due to that genotype heterogeneity and relatively small sample size make it easy to be masked. When another replication set was added, the above results were validated and a more powerful statistical significance was reached in the pooled analysis. In addition, we found that variant genotypes of rs10900598 and rs4245739 SNPs showed preferable treatment response, which may contribute to better survival than patients with wild-type genotypes.

The present study has several strengths. We used two relatively large cohorts from four independent oncological departments for the two-stage association analysis between *MDM4* SNPs and clinical outcome of advanced NSCLC patients. In addition, we also evaluated multiple *MDM4* polymorphisms individually classified by models including genotypic, dominant, recessive, or additive and collectively as haplotypes. However, we acknowledge that there are several limitations of the present study. First is the retrospective nature of the study. Second, although it was rational to conduct a pooled analysis with two similar databases, we cannot ignore certain differences such as different time interval of follow-up and the collection of clinical information. Third, the functional relevance of rs10900598 polymorphism on miRNAs-mediated *MDM4* regulation was not assessed because of the low DeltaS score. Further *in vitro* functional assays are needed to verify this genetic variant of *MDM4* gene as predictive biomarkers and to find the underlying biologic mechanisms.

In conclusion, we have identified SNPs in the 3′-UTR of *MDM4* gene among which rs4245739 and rs10900598 were associated with clinical outcome of advanced NSCLC patients treated with platinum-based chemotherapy, whereby the minor allele carriers have better overall survival and treatment response. Further studies are needed to investigate underlying precise mechanisms by which the *MDM4* SNPs affect outcome of advanced NSCLC patients.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

The Discovery set included 642 patients with histologically confirmed late-stage (III--IV) NSCLC who had received first-line platinum-based chemotherapy between March 2005 and January 2010 from oncological departments of Shanghai Zhongshan Hospital, Shanghai Chest Hospital, and Shanghai Changhai Hospital. Positive hits from the Discovery set were validated in patients with advanced NSCLC from a Replication cohort. This dataset included 330 newly diagnosed and histologically confirmed NSCLC cases in Shanghai Pulmonary Hospital between June 2010 and May 2013. Blood samples from all subjects were collected at the time of diagnosis prior to chemotherapy treatment.

All subjects were informed and provided written consents to participate in the study and to approve the use of their biological samples for genetic analysis. The study was approved by the Medical Ethics Committee of each participating institution.

Follow-up {#s4_2}
---------

Patients were interviewed face-to-face to collect demographic data including age, gender and smoking status. Those who had a low smoking frequency (\<1 cigarette per day) and duration (\<1 year) in their lifetime were defined as non-smokers. Clinical and follow-up information was obtained from medical records. Performance status was determined based on the Eastern Cooperative Oncology Group (ECOG) scale prior to treatment \[[@R25]\]. Patients' response to chemotherapy was assessed after the first two or three cycles and determined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 \[[@R26]\]. The disease control rate (DCR) included complete response (CR), partial response (PR) and stable disease (SD). The objective response rate (ORR) consisted of complete response (CR) and partial response (PR). Follow-up was performed per three months from the time of enrollment till death or the latest follow-up. OS was calculated as the first day to receive chemotherapy treatment to the day of death or to the latest follow-up. PFS was defined as the time from first treatment to the date of disease progression, death or last follow-up.

Chemotherapy regimens {#s4_3}
---------------------

All the patients enrolled in the study were given first-line platinum-based chemotherapy. The detailed chemotherapeutic regimens have been described previously \[[@R27]\]. All chemotherapeutic drugs were given intravenously, and the patients were treated for 2 to 6 cycles.

*MDM4* polymorphisms selection and genotyping {#s4_4}
---------------------------------------------

Genotype data for SNPs of *MDM4* gene were collected from two independent Chinese populations. We used the public HapMap SNP database (<http://www.hapmap.org/>) to identify the *MDM4* tagging SNPs within 3′-UTR on chromosome 1q32 by using the tagger algorithm with a minor allele frequency (MAF) cutoff of 0.05 and a correlation coefficient (r^2^) threshold of 0.8. Genomic DNA was extracted from peripheral blood lymphocytes using the Human Whole Blood Genomic DNA Extraction Kit (Qiagen, Valencia, CA). For each SNP, genotyping was performed using the TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Foster City, CA) following manufacturer\'s instructions. Approximately 15% of the samples were randomly selected for repeat genotyping by a different investigator, and the results were entirely concordant. SNPs were excluded from further analysis if they had call rates less than 95% or Hardy--Weinberg equilibrium *p*-values or MAFs less than 0.05.

Plasmid construction {#s4_5}
--------------------

The *MDM4* rs4245739A and rs4245739C allelic reporter constructs were generated by amplifying a 640-bp fragment of the *MDM4* 3′-UTR region from subjects homozygous for the rs4245739 AA or rs4245739 CC genotype. PCR primers used were as follows: 5′ -AACTCTAGAGGTAGTACGAACATAAAAATGC- 3′, and 5′- AACTCTAGACTGCATAAAGTAATCCATGG- 3′, which were also designed to include the *Xba* I restriction site sequence (T\^CTAGA). The PCR products were digested with *Xba* I (NEB Inc.) and ligated, respectively, into an appropriately digested pGL3-control vector (Promega). The constructs were designated as pGL3-rs4245739A and pGL3-rs4245739C, respectively. The inserts were confirmed by DNA sequencing.

Luciferase reporter assay {#s4_6}
-------------------------

A firefly luciferase reporter plasmid (pGL3-control, pGL3-rs4245739A or pGL3-rs4245739C), a renilla luciferase vector (pRL-SV40, Promega) plus 100 nmol of synthesized miR-887 mimics or negative control (Genepharma, China) were co-transfected into A549 cells with Lipofectamine 2000 (Invitrogen, CA). The relative luciferase units (RLU) were determined at 48h after transfection using the dual-luciferase reporter assay system (Promega; Madison, WI, USA) according to the manufacturer\'s instructions. Three independent experiments were performed and each was done in triplicate. Fold change was reported by setting the scores of the pGL3-control groups as one and normalizing the scores in other groups.

Statistical analysis {#s4_7}
--------------------

All statistical analyses were accomplished using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). Demographic and clinical characteristics were compared across genotype using Chi-square test for categorical variables. Hardy--Weinberg equilibrium was tested by comparing the observed genotype frequencies using a goodness-of-fit *χ* ^2^ test. For pairwise linkage disequilibrium analysis, D\' and r^2^ for each pair of SNPs were calculated by the Haploview Software \[[@R28]\]. Individual haplotype frequency was estimated based on the Bayesian algorithm using the PHASE 2.0 program (version 2.0.2) \[[@R29]\]. Logistic regression was used for calculating odds ratio (OR), 95% confidence intervals (CI) and trend test. Survival curves were computed according to the Kaplan-Meier method. Cox\'s Proportional Hazard Model was used to test the relationship between SNPs and survival of patients. For all SNPs with significant *p* values per genotype, the dominant, recessive and additive models were also calculated. All statistical analyses were two-sided and the differences were considered as statistically significant at *p* \< 0.05.
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